



#141/REPL 9


PATENT
ATTORNEY DOCKET NO. 08582/009002

Certificate of Mailing: Date of Deposit: December 17, 2002

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Susan M. Cannon

Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: F. Tufaro et al.

Art Unit: 1635

Serial No.: 09/592,007

Examiner: A. Wang

Filed: June 12, 2000

Customer No.: 21559

Title: Use of Viral Vectors and Charged Molecules for Gene Therapy

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

DEC 27 2002

RECEIVED

REPLY TO FINAL OFFICE ACTION

In reply to the final Office Action that was mailed in connection with the above-captioned case on June 17, 2002, as well as the Advisory Action that was mailed in this case on October 16, 2002, applicants submit the following Remarks.

REMARKS

In the October 16, 2002 Advisory Action, the prior obviousness rejection in this case was maintained. Applicants respectfully submit that this rejection should be withdrawn for the following reasons, as well as those discussed in their previous replies.

Central to this rejection is the combination of several references, Hodgson, Dyer, Mislick, and Marasco, and applicants submit that the rejection cannot stand, because there is not a sufficient basis for combining these references. In order for a combination of references to